We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) Up 1.8% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
It has been about a month since the last earnings report for Thermo Fisher Scientific (TMO - Free Report) . Shares have added about 1.8% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Thermo Fisher due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Thermo Fisher's Q3 Earnings & Revenues Top Estimates
Thermo Fisher Scientific Inc. delivered third-quarter 2026 adjusted earnings of $6.68 per share, up 15% year over year. The figure beat the Zacks Consensus Estimate by 4.4%.
Revenues rose 9% to $12.14 billion and surpassed the consensus mark of $11.92 billion by 1.8%. Results were supported by 6% organic revenue growth and improved operating profitability, reflecting the strength of the company's growth strategy and PPI Business System.
Life Sciences Solutions revenues increased 5.1% year over year to $2.72 billion. Segment income rose to $1.02 billion from $968 million, while the segment income margin expanded 20 basis points (bps) to 37.6%.
Laboratory Products and Biopharma Services remained the largest business, with revenues climbing 15% to $6.86 billion. Segment income increased to $1.07 billion from $868 million, while margin improved to 15.5% from 14.5%. The segment accounted for 56.5% of consolidated revenues.
Analytical Instruments revenues advanced 5.8% year over year to $2 billion. Segment income jumped to $538 million from $429 million, driving margin expansion to 26.9% from 22.6%. The 430-bps improvement was the largest among the company's four segments.
Specialty Diagnostics revenues declined 6.5% to $1.1 billion. However, segment income increased to $341 million from $321 million, while margin expanded to 31% from 27.4%. The improvement in profitability despite lower revenues highlights the segment's stronger operating efficiency.
Thermo Fisher Expands Operating Profitability
Adjusted operating income increased 15% year over year to $2.97 billion. The adjusted operating margin widened 120 bps to 24.5%, reflecting profitability improvements across all four business segments. On a GAAP basis, operating income rose 17% to $2.26 billion, while the operating margin improved to 18.6% from 17.4%. The cost of revenues totaled $6.95 billion, selling, general and administrative expenses were $1.86 billion, and research and development spending amounted to $348 million. GAAP earnings per share increased 9% to $4.64.
Thermo Fisher ended the third quarter with cash and cash equivalents of $5.46 billion compared with $9.85 billion at the end of 2025. Total assets stood at $114.23 billion, while long-term obligations amounted to $39.11 billion.
For the first nine months of 2026, net cash provided by operating activities increased to $5.87 billion from $4.36 billion a year earlier. Free cash flow rose to $4.62 billion from $3.32 billion. During this period, acquisitions net of cash acquired totaled $8.88 billion, share repurchases reached $4 billion, and dividends paid amounted to $511 million.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates revision.
VGM Scores
Currently, Thermo Fisher has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Thermo Fisher has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Image: Bigstock
Thermo Fisher (TMO) Up 1.8% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Thermo Fisher Scientific (TMO - Free Report) . Shares have added about 1.8% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Thermo Fisher due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Thermo Fisher's Q3 Earnings & Revenues Top Estimates
Thermo Fisher Scientific Inc. delivered third-quarter 2026 adjusted earnings of $6.68 per share, up 15% year over year. The figure beat the Zacks Consensus Estimate by 4.4%.
Revenues rose 9% to $12.14 billion and surpassed the consensus mark of $11.92 billion by 1.8%. Results were supported by 6% organic revenue growth and improved operating profitability, reflecting the strength of the company's growth strategy and PPI Business System.
Thermo Fisher's Q3 Segmental Performance Shows Mixed Trends
Life Sciences Solutions revenues increased 5.1% year over year to $2.72 billion. Segment income rose to $1.02 billion from $968 million, while the segment income margin expanded 20 basis points (bps) to 37.6%.
Laboratory Products and Biopharma Services remained the largest business, with revenues climbing 15% to $6.86 billion. Segment income increased to $1.07 billion from $868 million, while margin improved to 15.5% from 14.5%. The segment accounted for 56.5% of consolidated revenues.
Thermo Fisher's Analytical Instruments Margin Widens
Analytical Instruments revenues advanced 5.8% year over year to $2 billion. Segment income jumped to $538 million from $429 million, driving margin expansion to 26.9% from 22.6%. The 430-bps improvement was the largest among the company's four segments.
Specialty Diagnostics revenues declined 6.5% to $1.1 billion. However, segment income increased to $341 million from $321 million, while margin expanded to 31% from 27.4%. The improvement in profitability despite lower revenues highlights the segment's stronger operating efficiency.
Thermo Fisher Expands Operating Profitability
Adjusted operating income increased 15% year over year to $2.97 billion. The adjusted operating margin widened 120 bps to 24.5%, reflecting profitability improvements across all four business segments. On a GAAP basis, operating income rose 17% to $2.26 billion, while the operating margin improved to 18.6% from 17.4%. The cost of revenues totaled $6.95 billion, selling, general and administrative expenses were $1.86 billion, and research and development spending amounted to $348 million. GAAP earnings per share increased 9% to $4.64.
Thermo Fisher's Q3 Cash Flow Supports Financial Strength
Thermo Fisher ended the third quarter with cash and cash equivalents of $5.46 billion compared with $9.85 billion at the end of 2025. Total assets stood at $114.23 billion, while long-term obligations amounted to $39.11 billion.
For the first nine months of 2026, net cash provided by operating activities increased to $5.87 billion from $4.36 billion a year earlier. Free cash flow rose to $4.62 billion from $3.32 billion. During this period, acquisitions net of cash acquired totaled $8.88 billion, share repurchases reached $4 billion, and dividends paid amounted to $511 million.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates revision.
VGM Scores
Currently, Thermo Fisher has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Thermo Fisher has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.